Analysts Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $38.21

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have received an average recommendation of “Moderate Buy” from the twelve analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $38.2143.

A number of equities analysts have commented on the stock. Weiss Ratings cut shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. Truist Financial began coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price objective for the company. Wolfe Research began coverage on shares of Genmab A/S in a research report on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price for the company. HC Wainwright increased their target price on Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Finally, The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Terra Nova Asset Management LLC bought a new position in shares of Genmab A/S during the 4th quarter valued at $1,866,000. Perpetual Ltd bought a new stake in Genmab A/S in the fourth quarter worth $25,478,000. Assetmark Inc. lifted its stake in Genmab A/S by 2,423.8% in the fourth quarter. Assetmark Inc. now owns 233,852 shares of the company’s stock worth $7,203,000 after purchasing an additional 224,586 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Genmab A/S by 15.5% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 364,756 shares of the company’s stock worth $11,234,000 after purchasing an additional 48,894 shares during the last quarter. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in Genmab A/S during the fourth quarter valued at about $1,331,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Down 2.8%

GMAB stock opened at $27.91 on Friday. The company’s 50 day moving average is $26.65 and its 200 day moving average is $28.37. The stock has a market cap of $17.40 billion, a price-to-earnings ratio of 21.14, a price-to-earnings-growth ratio of 1.82 and a beta of 0.84. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. Genmab A/S has a 1-year low of $21.00 and a 1-year high of $35.43.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.